Atlas Trials

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Clinical trial NCT06383533 · UNKNOWN

Trial details

NCT number
NCT06383533
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Bile Duct Adenocarcinoma Non-ResectableHER2 Gene Mutation
Start date
2023-05-01
Primary completion
2025-05-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.